Weight-Loss Jabs Reduce Diabetic Eye Disease Risk, New Study Reveals
Groundbreaking research from the United States indicates that weight-loss medications, specifically Mounjaro, significantly lower the risk of diabetic retinopathy, an eye condition that can lead to irreversible blindness if left untreated. This finding emerges amidst recent safety warnings about similar drugs potentially causing vision loss in rare cases.
Study Details and Key Findings
The comprehensive study analysed data from more than 170,000 individuals with diabetes. Researchers discovered that patients taking Mounjaro, also known by its generic name tirzepatide, had a substantially reduced likelihood of being diagnosed with diabetic retinopathy compared to those relying solely on lifestyle interventions.
Furthermore, the medication appeared to slow progression to more dangerous stages of the disease. Diabetic retinopathy occurs when elevated blood sugar levels damage the retina, the light-sensitive tissue at the back of the eye responsible for transmitting visual signals to the brain.
It is estimated that over a quarter of people with diabetes develop this condition, equating to more than one million individuals in the United Kingdom alone.
Contrasting Safety Profiles
These promising results arrive just one week after UK health officials issued warnings about semaglutide, the active ingredient in similar weight-loss drugs Wegovy and Ozempic. The Medicines and Healthcare products Regulatory Agency (MHRA) acknowledged that semaglutide can, on rare occasions, trigger a condition called non-arteritic anterior ischemic optic neuropathy (NAION), which blocks blood flow to the optic nerves and causes vision loss.
Consequently, Wegovy prescriptions will now include a safety warning regarding this blindness risk. Additional reports from the United States have suggested that Mounjaro might potentially share this adverse effect, though the new study's findings challenge that concern.
Addressing Previous Concerns
Historically, there have been apprehensions that weight-loss injections could exacerbate diabetic retinopathy. A 2016 study concluded that approximately one in ten patients with existing retinopathy who took semaglutide experienced a worsening of their symptoms.
However, the research team behind the latest investigation asserts that this is not the case with Mounjaro. Dr. Szilard Kiss, a professor of ophthalmology at Weill Cornell Medicine in New York who led the study, stated that their findings suggest 'those with diabetic retinopathy may be less concerned that taking tirzepatide is going to make their condition worse.'
This distinction highlights the importance of differentiating between medications within the same therapeutic class and underscores the need for continued, rigorous post-market surveillance of all pharmaceutical products.
